Opioids in chronic non-cancer pain

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 5, 2011, Pages 705-720

  Chan, Bob Kwok Bun ^a   Tam, Lee Ka ^a   Wat, Chun Yin ^a   Chung, Yu Fai ^a   Tsui, Siu Lun ^a   Cheung, Chi Wai ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

analgesia; chronic; non cancer pain; opioid

Indexed keywords

BUPIVACAINE; CLONIDINE; FENTANYL; METHADONE; MIDAZOLAM; MORPHINE; NAPROXEN; NARCOTIC ANALGESIC AGENT; OPIATE ANTAGONIST; OXYCODONE; OXYMORPHONE; PHENYTOIN; PLACEBO; SUFENTANIL CITRATE; TILIDINE; TRAMADOL;

ALLODYNIA; ANALGESIA; BACKACHE; CHRONIC PAIN; COGNITION; CONSTIPATION; DIABETIC NEUROPATHY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPEPSIA; ENDOCRINE DISEASE; FAILED BACK SURGERY SYNDROME; FATIGUE; HEADACHE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERALGESIA; IMMUNOPATHOLOGY; LEG PAIN; LONG TERM CARE; LOW BACK PAIN; LOW DRUG DOSE; MUSCLE RIGIDITY; MUSCULOSKELETAL PAIN; MYOCLONUS; MYOFASCIAL PAIN; NAUSEA; NEUROPATHIC PAIN; OPIATE ADDICTION; OSTEOARTHRITIS; PAIN; PHANTOM PAIN; PHYSICAL CAPACITY; POSTHERPETIC NEURALGIA; PRURITUS; PSYCHOMOTOR DISORDER; PSYCHOMOTOR PERFORMANCE; QT PROLONGATION; QUALITY OF LIFE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SEDATION; SEXUAL DYSFUNCTION; SHORT COURSE THERAPY; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STOMACH EMPTYING; SUSTAINED DRUG RELEASE; TORSADE DES POINTES; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; VOMITING; XEROSTOMIA;

ANALGESICS, OPIOID; CHRONIC DISEASE; COGNITION; HUMANS; PAIN; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 79952592610     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.536335     Document Type: Review

References (134)

1. Model policy for the use of controlled substances for the treatment of pain. Federation of State Medical Boards of the United States, Dallas; 2004
2. Cousins MJ, Brennan F, Carr DB. Pain relief: a universal human right. Pain 2004;112(1-2):1-4 (Pubitemid 39371011)
3. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10(4):287-333
4. Eriksen J, Jensen MK, Sjogren P, et al. Epidemiology of chronic non-malignant pain in Denmark. Pain 2003;106(3):221-8 (Pubitemid 37505870)
5. Parsells Kelly J, Cook SF, Kaufman DW, et al. Prevalence and characteristics of opioid use in the US adult population. Pain 2008;138(3):507-13
6. Kalso E, Allan L, Dellemijn PL, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003;7(5):381-6 (Pubitemid 37101777)
7. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-30
8. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008;11(2 Suppl):S5-62
9. Recommendation for the appropriate use of opioids for persistent noncancer pain. A consensus statement prepared on behalf of the pain society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Royal College of Psychiatrists. The Pain Society, London; 2004
10. Eriksen J, Sjogren P, Bruera E, et al. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006;125(1-2):172-9 (Pubitemid 44498976)
11. Sullivan MD, Edlund MJ, Steffick D, Unutzer J. Regular use of prescribed opioids: association with common psychiatric disorders. Pain 2005;119(1-3):95-103 (Pubitemid 41752969)
12. United States of America v. Ronald A. McIver. 2005:4-745
13. Breivik H. Opioids in chronic non-cancer pain, indications and controversies. Eur J Pain 2005;9(2):127-30 (Pubitemid 40311831)
14. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9(2):105-21 (Pubitemid 351147828)
15. Trescot AM, Glaser SE, Hansen H, et al. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician 2008;11(2 Suppl):S181-200 (Pubitemid 351682085)
16. Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician 2007;10(3):479-91 (Pubitemid 46971301)
17. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006;174(11):1589-94 (Pubitemid 43829515)
18. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112(3):372-80 (Pubitemid 39550738)
19. Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 2007;146(2):116-27 (Pubitemid 351640015)
20. Deshpande A, Furlan A, Mailis-Gagnon A, et al. Opioids for chronic low-back pain. Cochrane Database Syst Rev 2007;(3):CD004959
21. Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis: a systematic review and metaanalysis. J Rheumatol 2007;34(3):543-55 (Pubitemid 46364009)
22. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006;3:CD006146
23. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010;(1):CD006605
24. Milligan K, Lanteri-Minet M, Borchert K, et al. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain 2001;2(4):197-204 (Pubitemid 32776971)
25. Rauck RL, Bookbinder SA, Bunker TR, et al. A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: improved physical functioning in the ACTION trial. J Opioid Manag 2007;3(1):35-43 (Pubitemid 350199792)
26. Jensen MK, Thomsen AB, Hojsted J. 10-year follow-up ofchronic non-malignant pain patients: opioid use, health related quality of life and health care utilization. Eur J Pain 2006;10(5):423-33 (Pubitemid 43786449)
27. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002;23(4):278-91 (Pubitemid 34462941)
28. Adams EH, Chwiecko P, Ace-Wagoner Y, et al. A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions-the ACCPT Study. Pain Pract 2006;6(4):254-64 (Pubitemid 44920925)
29. Allan L, Richarz U, Simpson K, Slappendel R Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine 2005;30(22):2484-90 (Pubitemid 41669082)
30. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage 2003;25(6):559-77 (Pubitemid 36637063)
31. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain 2004;109(3):514-19 (Pubitemid 38638730)
32. Vogt MT, Kwoh CK, Cope DK, et al. Analgesic usage for low back pain: impact on health care costs and service use. Spine 2005;30(9):1075-81 (Pubitemid 40663916)
33. Webster BS, Verma SK, Gatchel RJ. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use. Spine 2007;32(19):2127-32 (Pubitemid 47359620)
34. Zacny J, Bigelow G, Compton P, et al. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003;69(3):215-32 (Pubitemid 36293934)
35. Mahmud MA, Webster BS, Courtney TK, et al. Clinical management and the duration of disability for work-related low back pain. J Occup Environ Med 2000;42(12):1178-87 (Pubitemid 32014681)
36. Collett BJ. Opioid tolerance: the clinical perspective. Br J Anaesth 1998;81(1):58-68
37. Sjogren P, Thunedborg LP, Christrup L, et al. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiol Scand 1998;42(9):1070-5 (Pubitemid 28478125)
38. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006;104(3):570-87
39. Athanasos P, Smith CS, White JM, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain 2006;120(3):267-75 (Pubitemid 43172861)
40. Doverty M, White JM, Somogyi AA, et al. Hyperalgesic responses in methadone maintenance patients. Pain 2001;90(1-2):91-6 (Pubitemid 32146561)
41. Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 2005;103(1):147-55 (Pubitemid 40943147)
42. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006;7(1):43-8 (Pubitemid 43097262)
43. Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 2002;22(18):8312-23 (Pubitemid 35379137)
44. Sjogren P, Jensen NH, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994;59(2):313-16 (Pubitemid 24348916)
45. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 2001;63(2):139-46 (Pubitemid 32488928)
46. Raehal KM, Bohn LM. Mu opioid receptor regulation and opiate responsiveness. AAPS J 2005;7(3):E587-91
47. Wang HY, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 2005;135(1):247-61 (Pubitemid 41219753)
48. Yoburn BC, Gomes BA, Rajashekara V, et al. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo. Synapse 2003;47(2):109-16 (Pubitemid 36020282)
49. Noble F, Cox BM. Differential desensitization of mu-and delta-opioid receptors in selected neural pathways following chronic morphine treatment. Br J Pharmacol 1996;117(1):161-9
50. Sim-Selley LJ, Selley DE, Vogt LJ, et al. Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. J Neurosci 2000;20(12):4555-62 (Pubitemid 30396621)
51. Bohn LM, Lefkowitz RJ, Caron MG. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci 2002;22(23):10494-500 (Pubitemid 35416886)
52. Yabaluri N, Medzihradsky F. Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling. Mol Pharmacol 1997;52(5):896-902 (Pubitemid 27484183)
53. Saeki S, Yaksh TL. Suppression of nociceptive responses by spinal mu opioid agonists: effects of stimulus intensity and agonist efficacy. Anesth Analg 1993;77(2):265-74 (Pubitemid 23221424)
54. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991;251(4989):85-7 (Pubitemid 21916858)
55. Marek P, Ben-Eliyahu S, Gold M, Liebeskind JC. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res 1991;547(1):77-81
56. Mao J. Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep 2006;10(1):67-70
57. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995;62(3):259-74
58. Gardell LR, Wang R, Burgess SE, et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002;22(15):6747-55 (Pubitemid 35386431)
59. Vanderah TW, Suenaga NM, Ossipov MH, et al. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci 2001;21(1):279-86 (Pubitemid 32098751)
60. King T, Ossipov MH, Vanderah TW, et al. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals 2005;14(4):194-205 (Pubitemid 41417108)
61. Fishbain DA, Cole B, Lewis JE, et al. Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med 2009;10(5):829-39
62. Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain-a systematic review of randomized controlled trials. Pain 2006;126(1-3):91-101 (Pubitemid 44751958)
63. Drake R, Longworth J, Collins JJ. Opioid rotation in children with cancer. J Palliat Med 2004;7(3):419-22 (Pubitemid 38980577)
64. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002;20(1):348-52 (Pubitemid 34032631)
65. Terner JM, Barrett AC, Lomas LM, et al. Influence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains. Pain 2006;122(1-2):90-101
66. Chindalore VL, Craven RA, Yu KP, et al. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain 2005;6(6):392-9 (Pubitemid 40804344)
67. Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 1999;289(2):1048-53 (Pubitemid 29191265)
68. Eilers H, Philip LA, Bickler PE, et al. The reversal of fentanyl-induced tolerance by administration of 'small-dose' ketamine. Anesth Analg 2001;93(1):213-14 (Pubitemid 32601182)
69. Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician 2009;12(3):679-84
70. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008;35(2):214-28
71. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005;7(5):R1046-51
72. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349(20):1943-53 (Pubitemid 37409712)
73. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 2005;293(24):3043-52 (Pubitemid 40965075)
74. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11(2 Suppl):S105-20 (Pubitemid 351682081)
75. Stephanou A, Fitzharris P, Knight RA, Lightman SL. Characteristics and kinetics of proopiomelanocortin mRNA expression by human leucocytes. Brain Behav Immun 1991;5(4):319-27
76. Peterson PK, Molitor TW, Chao CC. The opioid-cytokine connection. J Neuroimmunol 1998;83(1-2):63-9 (Pubitemid 28280952)
77. Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain 2010;26(5):374-8078
78. Sacerdote P, Bianchi M, Manfredi B, Panerai AE. Effects of tramadol on immune responses and nociceptive thresholds in mice. Pain 1997;72(3):325-30 (Pubitemid 27390731)
79. Manchikanti L. National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician 2007;10(3):399-424 (Pubitemid 46971294)
80. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain 2008;9(1):28-36 (Pubitemid 350309727)
81. Petraglia F, Porro C, Facchinetti F, et al. Opioid control of LH secretion in humans: menstrual cycle, menopause and aging reduce effect of naloxone but not of morphine. Life Sci 1986;38(23):2103-10 (Pubitemid 16122643)
82. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician 2006;74(8):1347-54 (Pubitemid 44607306)
83. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63(7):649-71 (Pubitemid 36408072)
84. Yuan CS, Foss JF. Antagonism of gastrointestinal opioid effects. Reg Anesth Pain Med 2000;25(6):639-42
85. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysunction. Am J Surg 2001;182:11S-18S (Pubitemid 34072942)
86. Tassinari D, Sartori S, Tamburini E, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 2008;11(3):492-501 (Pubitemid 351440551)
87. Leyendecker P, Hopp M, Bosse B, et al. Bowel Function Index (BFI), a new validated questionaire for assessing opioid induced constipation. Proceeding of the 12th IASP World Congress on Pain; 17-22 August 2008; Glasgow, Scotland, UK
88. Fishman J, Roffwarg H, Helman L. Disposition ofnaloxone-7,8-3H in normal and narcotic-dependent men. J Pharmacol Exp Ther 1973;187:575-80
89. Sykes NP. An investigation of the ability of oral naxolone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 2006;10:135-44
90. McNicol E, Boyce DB, Schumann R, Carr D. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systemic review and meta-analysis of randomized controlled trials. Pain Med 2008;9:634-59
91. McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev 2008;2:CD006332
92. Ahmedzai S. New approaches to pain control in patients with cancer. Eur J Cancer 1997;33(Suppl 6):S8-14
93. Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006;368(9536):704 (Pubitemid 44223697)
94. Pickworth WB, Neidert GL, Kay DC Morphinelike arousal by methadone during sleep. Clin Pharmacol Ther 1981;30(6):796-804 (Pubitemid 12198105)
95. Slatkin N, Rhiner M. Treatment of opioid-induced delirium with acetylcholinesterase inhibitors: a case report. J Pain Symptom Manage 2004;27(3):268-73 (Pubitemid 38317064)
96. Ramaekers JG. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. J Clin Psychiatry 2003;64(1):20-9 (Pubitemid 36182225)
97. Byas-Smith MG, Chapman SL, Reed B, Cotsonis G. The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain 2005;21(4):345-52 (Pubitemid 40881145)
98. Budd RD, Muto JJ, Wong JK. Drugs of abuse found in fatally injured drivers in Los Angeles County. Drug Alcohol Depend 1989;23(2):153-8 (Pubitemid 19103795)
99. Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, Pappagallo M. Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage 1998;15(3):185-94 (Pubitemid 28169141)
100. Lyss AP, Portenoy RK. Strategies for limiting the side effects of cancer pain therapy. Semin Oncol 1997;24(5 Suppl 16):S16-28-34
101. Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain 1998;74(1):5-9 (Pubitemid 28097723)
102. Han PK, Arnold R, Bond G, et al. Myoclonus secondary to withdrawal from transdermal fentanyl: case report and literature review. J Pain Symptom Manage 2002;23(1):66-72 (Pubitemid 34093885)
103. Krantz MJ, Mehler PS. Synthetic opioids and QT prolongation. Arch Intern Med 2003;163(13):1615; author reply
104. Walker PW, Klein D, Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. Pain 2003;103(3):321-4 (Pubitemid 36638820)
105. Katchman AN, McGroary KA, Kilborn MJ, et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther 2002;303(2):688-94 (Pubitemid 35231242)
106. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81(2):299-307
107. Skjervold B, Bathen J, Spigset O. Methadone and the QT interval: relations to the serum concentrations of methadone and its enantiomers (R)-methadone and (S)-methadone. J Clin Psychopharmacol 2006;26(6):687-9 (Pubitemid 44772761)
108. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005;14(11):747-53 (Pubitemid 41684467)
109. Cardiac Vigilance Recommended for Methadone. 2005. Available from: http://www. medsafe.govt.nz/profs/puarticles/methadone.htm [Cited]
110. International Classification of Disease (ICD-10). 2007. Available from: http://www.who.int/classifications/icd/en [Cited April 2010]
111. Savage SR, Joranson DE, Covington EC, et al. Definitions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage 2003;26(1):655-67 (Pubitemid 36802289)
112. Holding MY, Saulino MF, Overton EA, et al. Interventions in chronic pain management. 1. Update on important definitions in pain management. Arch Phys Med Rehabil 2008;89(3 Suppl 1):S38-40 (Pubitemid 351754819)
113. Michna E, Ross EL, Hynes WL, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 2004;28(3):250-8 (Pubitemid 39158807)
114. Reid MC, Engles-Horton LL, Weber MB, et al. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med 2002;17(3):173-9 (Pubitemid 34603843)
115. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 2006;6:46
116. Edlund MJ, Steffick D, Hudson T, et al. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain 2007;129(3):355-62 (Pubitemid 46754578)
117. Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 2007;11(5):490-518 (Pubitemid 46670780)
118. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005;6(6):432-42 (Pubitemid 43110296)
119. Passik SD, Kirsh KL, Casper D. Addition-related assessment tools and pain management: instruments for screening, treatment planning, and monitoring compliance. Pain Med 2008;9(S2):S145-66
120. Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10(2):131-46
121. Passik SD, Kirsh KL, Whitcomb L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther 2004;26(4):552-61 (Pubitemid 38586456)
122. Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the current opioid misuse measure. Pain 2007;130(1-2):144-56 (Pubitemid 46843461)
123. Katz N, Fanciullo GJ. Role ofurine toxicology testing in the management of chronic opioid therapy. Clin J Pain 2002;18(4 Suppl):S76-82 (Pubitemid 34815397)
124. Manchikanti L, Atluri S, Trescot AM, Giordano J. Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility. Pain Physician 2008;11(2 Suppl):S155-80 (Pubitemid 351682084)
125. Arnold RM, Han PK, Seltzer D. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. Am J Med 2006;119(4):292-6
126. Fishman SM, Bandman TB, Edwards A, Borsook D. The opioid contract in the management of chronic pain. J Pain Symptom Manage 1999;18(1):27-37 (Pubitemid 29344633)
127. Fishman SM, Kreis PG. The opioid contract. Clin J Pain 2002;18(4 Suppl):S70-5 (Pubitemid 34815396)
128. Burchman SL, Pagel PS. Implementation of a formal treatment agreement for outpatient management of chronic nonmalignant pain with opioid analgesics. J Pain Symptom Manage 1995;10(7):556-63
129. Collen M. Opioid contracts and random drug testing for people with chronic pain-think twice. J Law Med Ethics 2009;37(4):841-5
130. Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abuse Treat 2007;32(2):189-98 (Pubitemid 46240723)
131. Akbik H, Butler SF, Budman SH, et al. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manage 2006;32(3):287-93 (Pubitemid 44376443)
132. Butler SF, Fernandez K, Benoit C, et al. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain 2008;9(4):360-72
133. Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 2004;112(1-2):65-75 (Pubitemid 39371021)
134. Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain 2006;7(9):671-81 (Pubitemid 44291603)